Takeda's Alunbrig surpasses Pfizer therapy in Phase III lung cancer trial
Takeda (TYO: 4502) has announced that Alunbrig (brigatinib) has passed its primary endpoint for use in anaplastic lymphoma kinase-positive locally advanced or metastatic non-small cell lung cancer (ALK+NSCLC).
The results, gathered during Phase III of the ALTA trial, show a statistically-significant increase in progression-free survival rates in ALK+NSCLC patients when compared to Xalkori (crizotinib), the Pfizer- (NYSE:PFE) developed therapy.
"This represents a major milestone for the Alunbrig program." said Jesús Gomez-Navarro, vice president and head of oncology R&D at Takeda. "We are encouraged by the data, which demonstrated a statistically-significant improvement in progression-free survival versus crizotinib in patients with ALK+ advanced NSCLC, and look forward to beginning discussions with regulatory authorities as we seek to expand Alunbrig's indication into the frontline setting."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze